Compare Seagate Technology Holdings PLC (STX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Seagate Technology (STX) trades at $746.86, down 0.85% amid recent sector volatility. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $5.71 versus $5.10 expected, and robust profitability metrics including 26.11% net margin and 371.53% ROE. However, technical indicators signal bearish momentum with the stock trading near support at $746. Recent news highlights competitive pressures as Toshiba plans AI storage expansion, threatening Seagate's pricing power in the high-capacity drive market.

Outlook remains mixed with 53.85% analyst buy ratings and $1,130 consensus price target suggesting 51% upside, but competitive risks from Toshiba's production plans and elevated valuations (P/E 51.33) pose headwinds. The company's projected 2026 revenue growth to $12.2B and net income of $3.2B support long-term AI infrastructure demand thesis, though near-term volatility may persist.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.